Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM

Why It Matters

The data confirm that early, uninterrupted TTR stabilization delivers durable clinical benefit, shaping treatment guidelines and reinforcing the value of prompt diagnosis in ATTR‑CM. This long‑term efficacy and safety profile strengthens acoramidis’ market position against competing stabilizers.

Key Takeaways

• Continuous acoramidis reduced all-cause mortality vs delayed start at 54 months
• Early treatment gap persisted despite crossover, indicating irreversible disease progression
• TTR stabilization >90% surpasses tafamidis, driving superior outcomes
• No new safety signals observed over 4.5 years of therapy
• OLE enrolled 389 ATTR‑CM patients, confirming durability across disease subtypes

Pulse Analysis

Transthyretin amyloid cardiomyopathy (ATTR‑CM) remains a high‑mortality heart disease, driven by misfolded TTR deposits that stiffen the myocardium. While tafamidis was the first oral stabilizer to gain approval, its modest TTR binding left clinicians seeking more potent options. Acoramidis, a near‑complete stabilizer achieving over 90% tetramer occupancy, entered the market with promising phase 3 data, but long‑term durability was still unproven. The recent open‑label extension (OLE) of the ATTRibute‑CM trial fills that gap, delivering one of the longest follow‑up periods for any ATTR‑CM therapy.

The OLE’s 389 participants were split between continuous acoramidis exposure and a delayed‑initiation cohort that crossed over after 30 months on placebo. By month 54, the continuous group showed incremental reductions in all‑cause mortality, cardiovascular mortality, and first cardiovascular hospitalization compared with the delayed group. Notably, the mortality gap persisted despite crossover, suggesting that disease progression occurring during the untreated window may be partially irreversible. These findings underscore the clinical imperative of early diagnosis—often via echocardiography, cardiac MRI, or nuclear imaging—and immediate therapy initiation to halt amyloid deposition before irreversible myocardial damage accrues.

For cardiology practices and health systems, the OLE data translate into actionable strategies: prioritize screening of older patients with unexplained heart failure and characteristic imaging signs, and consider acoramidis as first‑line therapy given its superior TTR stabilization and safety record. The absence of new adverse events over 4.5 years reassures payers about long‑term cost‑effectiveness, while the demonstrated efficacy advantage may shift prescribing patterns away from tafamidis. As the ATTR‑CM market expands, manufacturers will likely invest in head‑to‑head trials and real‑world evidence to further differentiate their agents, but for now acoramidis sets a new benchmark for durability in this rare but deadly disease.